Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE^® assays

Keywords

Apolipoprotein E4 / Alzheimer’s disease / disease modifying therapy / chemiluminescent enzyme immunoassay

References

[1] Liu CC,Kanekiyo T,Xu H,Bu G.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.Nat Rev Neurol.2013;9:106-18.

[2] Corder EH,Saunders AM,Strittmatter WJ,Schmechel DE,Gaskell PC,Small GW,et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families.Science.1993;261:921-3.

[3] Farrer LA,Cupples LA,Haines JL,Hyman B,Kukull WA,Mayeux R,et al.Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.JAMA.1997;278:1349-56.

[4] Verghese PB,Castellano JM,Holtzman DM.Apolipoprotein E in Alzheimer’s disease and other neurological disorders.Lancet Neurol.2011;10:241-52.

[5] Budd Haeberlein S,Aisen PS,Barkhof F,Chalkias S,Chen T,Cohen S,et al.Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease.J Prev Alzheimers Dis.2022;9:197-210.

[6] van Dyck CH,Swanson CJ,Aisen P,Bateman RJ,Chen C,Gee M,et al.Lecanemab in early Alzheimer’s disease.N Engl J Med.2023;388:9-21.

[7] Cummings J,Rabinovici GD,Atri A,Aisen P,Apostolova LG,Hendrix S,et al.Aducanumab: appropriate use recommendations update.J Prev Alzheimers Dis.2022;9:221-30.

[8] Cummings J,Apostolova L,Rabinovici GD,Atri A,Aisen P,Greenberg S,et al.Lecanemab: appropriate use recommendations.J Prev Alzheimers Dis.2023;10:362-77.

[9] Filippi M,Cecchetti G,Spinelli EG,Vezzulli P,Falini A,Agosta F.Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies: a systematic review.JAMA Neurol.2022;79:291-304.

[10] Siest G,Pillot T,Régis-Bailly A,Leininger-Muller B,Steinmetz J,Galteau MM,et al.Apolipoprotein E: an important gene and protein to follow in laboratory medicine.Clin Chem.1995;41:1068-86.

[11] Calero O,Hortigüela R,Bullido MJ,Calero M.Apolipoprotein E genotyping method by real time PCR, a fast and cost-effective alternative to the TaqMan^® and FRET assays.J Neurosci Methods.2009;183:238-40.

[12] Zhong L,Xie YZ,Cao TT,Wang Z,Wang T,Li X,et al.A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism.Mol Neurodegener.2016;11:2.

[13] Dupuy AM,Badiou S,Ritchie K,Mas E,Descomps B,Cristol JP,et al.Discrepancies between apolipoprotein E phenotyping and genotyping in the elderly.Clin Chem Lab Med.2001;39:405-13.

[14] Kataoka S,Paidi M,Howard BV.Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype.Clin Chem.1994;40:11-3.

[15] Uchida Y,Ito S,Nukina N.Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms.J Clin Lab Anal.2000;14:260-4.

[16] Niederkofler EE,Tubbs KA,Kiernan UA,Nedelkov D,Nelson RW.Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins.J Lipid Res.2003;44:630-9.

[17] Badrnya S,Doherty T,Richardson C,McConnell RI,Lamont JV,Veitinger M,et al.Development of a new biochip array for APOE4 classification from plasma samples using immunoassay-based methods.Clin Chem Lab Med.2018;56:796-802.

[18] Ehara H,Yamamoto-Honda R,Kitazato H,Takahashi Y,Kawazu S,Akanuma Y,et al.ApoE isoforms, treatment of diabetes and the risk of coronary heart disease.World J Diabetes.2012;3:54-9.

[19] Stavljenic-Rukavina A,Sertic J,Salzer B,Dumic M,Radica A,Fumic K,et al.Apolipoprotein E phenotypes and genotypes as determined by polymerase chain reaction using allele-specific oligonucleotide probes and the amplification refractory mutation system in children with insulin-dependent diabetes mellitus.Clin Chim Acta.1993;216:191-8.

[20] Hixson JE,Vernier DT.Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.J Lipid Res.1990;31:545-8.

[21] Belloy ME,Napolioni V,Greicius MD.A quarter century of APOE and Alzheimer’s disease: progress to date and the path forward.Neuron.2019;101:820-38.

[22] Husain MA,Laurent B,Plourde M.APOE and Alzheimer’s disease: from lipid transport to physiopathology and therapeutics.Front Neurosci.2021;15:630502.

[23] Iwatsubo T,Iwata A,Suzuki K,Ihara R,Arai H,Ishii K,et al.Japanese Alzheimer’s Disease Neuroimaging InitiativeSun CK,Beckett LA,Petersen RC,Weiner MW,Aisen PS,Donohue MCAlzheimer’s Disease Neuroimaging InitiativeJapanese and North American Alzheimer’s disease neuroimaging initiative studies: harmonization for international trials.Alzheimers Dement.2018;14:1077-87.

[24] Veiga S,Rodríguez-Martín A,Garcia-Ribas G,Arribas I,Menacho-Román M,Calero M.Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers.Sci Rep.2020;10:2138.

[25] Palmqvist S,Stomrud E,Cullen N,Janelidze S,Manuilova E,Jethwa A,et al.An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease.Alzheimers Dement.2023;19:1204-15.

[26] Srivastava RAK.Regulation of the apolipoprotein E by dietary lipids occurs by transcriptional and post-transcriptional mechanisms.Mol Cell Biochem.1996;155:153-62.

[27] Janelidze S,Bali D,Ashton NJ,Barthélemy NR,Vanbrabant J,Stoops E,et al.Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease.Brain.2023;146:1592-601.

[28] Nojima H,Ito S,Kushida A,Abe A,Motsuchi W,Verbel D,et al.Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE^® system.Ann Clin Transl Neurol.2022;9:1898-909.

[29] Musso G,Cosma C,Zaninotto M,Gabelli C,Basso D,Plebani M.Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer’s disease.Clin Chem Lab Med.2023;61:e53-6.